Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte has dosed the first participant in its Phase 1, first-in-human study of VAX-A1, a vaccine candidate targeting Group A Streptococcus. The randomized, double-blind, placebo-controlled study will enroll approximately 80 healthy adults in two stages, with topline data expected in the second half of 2027.
Key figures
- Drug Name
- VAX-A1
- Phase Of Trial
- Phase 1
- Total participants
- 80
- Us economic impact
- $6 billion
- Global annual cases
- 800 million
- Global annual deaths
- 600,000
- Stage 1 participants
- 12
- Stage 2 participants
- 68
- Topline data expected
- H2 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.